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Pituitary adenylate-cyclase-activating
polypeptide (PACAP): another novel target
for treatment of primary headaches?
Messoud Ashina1* and Paolo Martelletti2,3
Since its discovery in 1989 [1], pituitary adenylate cy-
clase activating peptide (PACAP) has emerged as a key
molecule in primary headaches. New insights on the role
of PACAP in migraine [2] have now been translated into
interest in exploring the migraine preventative effect of
monoclonal antibodies against PACAP and monoclonal
antibodies against PAC1 receptor (https://clinicaltrials.gov/
ct2/show/NCT03238781?term=AMG301&rank=1 ;[3]).
Given that PACAP is a multifunctional peptide in-
volved in various cellular and physiological responses, it
is important to understand and further explore its func-
tion in non-headache mechanisms which might be rele-
vant in context to primary headaches. This TJHP
thematic series provide an overview of the history of the
discovery of PACAP and its three receptors [4] and
summarize PACAP and its receptor distribution in mi-
graine relevant structures [5]. Furthermore, the readers
will get insights on the role of PACAP in regulating the
production of inflammatory mediators [6] and important
role of degranulation of dural mast cells via a yet un-
known receptor in migraine induction by PACAP38 [7].
The series also cover possible mechanisms of PACAP38-
induced migraine, outline future directions [8] and dis-
cuss how PACAP may cross the blood brain barrier [9]
and its implication for PACAP induced migraine. To fur-
ther elucidate the role of PACAP in primary headaches
it is important to study its role in regulation of sleep
[10] and vascular tone [11] which are covered by excel-
lent review articles in the special issue Both aspects are
important in context of tolerability and safety of future
anti PACAP drugs for prevention of primary headaches.
Altogether our aim is to provide a comprehensive series
of reviews focusing on PACAP as an emerging molecule
in primary headache headaches.
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